Malaria Studies in Cambodia

August 17, 2018 updated by: National Institute of Allergy and Infectious Diseases (NIAID)

Studies of P. Vivax and P. Falciparum Malaria in Cambodia

This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following factors confer protection against malaria and associated anemia: certain blood groups, the hemoglobin E variant, G6PD-deficiency and alpha-thalassemia. Malaria is caused by parasites (P. falciparum and P. vivax) that are transmitted to humans through mosquito bites. This protocol includes two studies, a cohort study and a P. vivax collection study.

Individuals are eligible for enrollment in the studies as follows:

Cohort study:

Residents of all ages of Kandal, Ekapheap and Sangkumthmey villages (Thmar Da commune) who plan to remain in Thmar Da commune for the next 5 years.

P. vivax collection study:

2 years of age and older

Participating in NIAID protocol 05-I- N210 ( Severe Malaria and Anti-malarial Drug Resistance in Cambodia ) and diagnosed with P. vivax malaria

Participants undergo the following procedures:

Cohort study:

Baseline evaluation, including the following:

  • Collection of demographic information
  • Malaria history, temperature measurement and review of current symptoms, if any
  • Blood draw of 300 microliters
  • Additional blood draw of 10 milliliters in selected adults 18 years of age and older

Treatment with artesunate-piperaquine at a commune health post for subjects who develop malaria

Contact once a year for 5 years to determine continued residency in Thmar Da commune

P. vivax collection study:

  • Medical history and physical examination
  • Hemoglobin level measurement
  • Blood draw
  • Treatment with chloroquine
  • Blood draw 3 to 5 weeks after treatment in some patients 18 years of age or older

Study Overview

Status

Completed

Conditions

Detailed Description

Cohort study. Hemoglobin (Hb) and red blood cell (RBC) polymorphisms that give rise to HbE, alpha-thalassemia, G6PD-deficiency, and ABO blood groups occur at high frequency along the Thailand-Cambodia border, where Plasmodium vivax and P. falciparum have been and continue to be transmitted. To determine whether these Hb/RBC polymorphisms have been naturally selected because they confer protection against malaria and malaria-associated anemia, we will conduct a cohort study of ethnic Khmer in Cambodia. Approximately 1000 individuals of all ages will be genotyped for the four polymorphisms listed above and then followed for 5 years to determine the mean incidence rates for both P. vivax and P. falciparum malaria, stratified by genotype. Incidence rate ratios (IRRs) will be calculated for each polymorphism relative to the wildtype genotype. Differences between Hb levels during acute episodes of malaria and Hb levels at baseline will also be calculated to determine if Hb/RBC polymorphisms influence the degree of malaria-associated anemia.

P. vivax collection study. Unlike P. falciparum, P. vivax cannot be efficiently cultivated in vitro. Improved cultivation methods are needed to make progress on nearly all aspects of P. vivax malariology, including pathogenesis, naturally-acquired immunity, vaccination, and antimalarial drug resistance. We plan to improve both short- and long-term cultivation methods in order to test various hypotheses of P. vivax pathogenesis and protection. Using freshly obtained parasite isolates from individuals with P. vivax malaria, we will test whether Hb/RBC polymorphisms influence potentially pathogenic properties of P. vivax parasites, such as their ability to bind non-infected RBCs and other host cells. It is believed that P. vivax selectively invades reticutocytes. This tropism has frustrated attempts at long-term cultivation of this parasite, which requires a constant source of reticulocyte-rich blood not easily obtained even in developed countries. The host reticulocyte receptor that mediates the highly selective tropism of P. vivax has not been identified. Fresh P. vivax parasites will also be used in in vitro experiments to identify the putative receptor that defines reticulocyte tropism. Any P. vivax ligand that bound selectively to a reticulocyte receptor will then be discovered and worked up as a promising vaccine candidate.

Study Type

Observational

Enrollment (Actual)

1978

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Cambodia
      • Phnom Penh, Cambodia
        • National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H
      • Preah Vihear Province, Cambodia
        • Preah Vihear Referral Hospital
      • Ratanakiri Province, Cambodia
        • Ratanakiri Referral Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 100 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

  • INCLUSION CRITERIA: (Cohort Study)

Resident of Kandal, Ekapheap, and Sangkumthmey villages (Thmar Da commune), and no plans to leave the Thmar Da commune for the next 5 years.

Willingness to participate in the study as evidenced by informed consent of subjects or his/her parent or guardian, and willingness to come to commune health posts if he/she develops fever or other symptoms of malaria.

Individuals of all ages will be enrolled.

EXCLUSION CRITERIA: (Cohort Study)

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

INCLUSION CRITERIA: (P. vivax Collection Study)

P. vivax malaria (mono-infection).

Willingness to participate in the study as evidenced by informed consent of subjects or his/her parent or guardian.

Age greater than or equal to 2.

Hematocrit greater than or equal to 25%.

EXCLUSION CRITERIA: (P. vivax Collection Study)

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

Pregnancy.

Prior use of antimalarials during the past 2 months.

INCLUSION CRITERIA: (Cord and Peripheral Blood Collection Study)

Healthy male or female adults greater than or equal to 18 years old or healthy pregnant female adults greater than or equal to 18 years old.

Willingness to participate in the study as evidenced by informed consent.

EXCLUSION CRITERIA: (Cord and Peripheral Blood Collection Study)

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

INCLUSION CRITERIA: (Collection of peripheral blood for identifying and isolating memory B cells)

Healthy male or non- pregnant female adults greater than or equal to 18 years old.

Previous enrollment on the P. vivax collection study.

Willingness to participate in the study as evidenced by written informed consent.

EXCLUSION CRITERIA: (Collection of peripheral blood for identifying and isolating memory B cells)

For the follow-up blood draw (250 mL), symptomatic parasitemia with any species of Plasmodium.

For the follow-up blood draw (250 mL), hemoglobin level <9 g/dL.

For the follow-up blood draw (250 mL), weight <45 kg.

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric illness).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 24, 2008

Study Completion

December 5, 2013

Study Registration Dates

First Submitted

April 19, 2008

First Submitted That Met QC Criteria

April 19, 2008

First Posted (Estimate)

April 22, 2008

Study Record Updates

Last Update Posted (Actual)

August 20, 2018

Last Update Submitted That Met QC Criteria

August 17, 2018

Last Verified

December 5, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 999908094
  • 08-I-N094

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malaria

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe